DexCom, Inc. (NASDAQ:DXCM – Get Free Report) was the recipient of some unusual options trading activity on Thursday. Investors purchased 10,495 call options on the company. This is an increase of approximately 87% compared to the average daily volume of 5,616 call options.
DexCom Stock Performance
Shares of DexCom stock opened at $124.34 on Friday. The firm has a market capitalization of $49.24 billion, a P/E ratio of 94.92, a P/E/G ratio of 2.37 and a beta of 1.20. DexCom has a 52 week low of $74.75 and a 52 week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The firm’s 50 day moving average is $131.13 and its two-hundred day moving average is $118.30.
DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 14.95% and a return on equity of 28.31%. Research analysts forecast that DexCom will post 1.76 EPS for the current fiscal year.
Insider Activity at DexCom
Hedge Funds Weigh In On DexCom
Several hedge funds have recently added to or reduced their stakes in DXCM. Stableford Capital II LLC grew its position in shares of DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after acquiring an additional 88 shares during the last quarter. D Orazio & Associates Inc. grew its position in shares of DexCom by 0.8% during the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after acquiring an additional 93 shares during the last quarter. Gulf International Bank UK Ltd grew its position in shares of DexCom by 0.3% during the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after acquiring an additional 93 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of DexCom by 10.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after acquiring an additional 98 shares during the last quarter. Finally, Harbor Investment Advisory LLC grew its position in shares of DexCom by 13.1% during the first quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after acquiring an additional 100 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages have recently issued reports on DXCM. Raymond James increased their price target on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday. Canaccord Genuity Group increased their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Finally, Citigroup increased their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $141.67.
Check Out Our Latest Stock Analysis on DexCom
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles
- Five stocks we like better than DexCom
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the Nikkei 225 index?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Health Care Stocks Explained: Why You Might Want to Invest
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.